Cassiopea SpA   Report issue

For profit Phase 3
Founded: Lainate Italy (2013)

Organization Overview

First Clinical Trial
2015
NCT02608450
First Marketed Drug
2020
clascoterone (Winlevi)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cassiopea SpA | Cassiopea S.p.A. | CASSIOPEA SPA

Active Ingredients

Marketed Drugs (1)

clascoterone (Winlevi) (2020)

Drugs in Phase 3 Trials (1)

clascoterone (Winlevi) (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1